Zoetis Inc. (NYSE:ZTS) Shares Bought by TCTC Holdings LLC

TCTC Holdings LLC increased its position in Zoetis Inc. (NYSE:ZTS) by 2.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,760 shares of the company’s stock after purchasing an additional 1,153 shares during the quarter. TCTC Holdings LLC’s holdings in Zoetis were worth $8,159,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new stake in shares of Zoetis during the third quarter worth about $33,000. Quarry LP increased its holdings in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the last quarter. LRI Investments LLC acquired a new position in shares of Zoetis in the 1st quarter valued at approximately $43,000. Fortitude Family Office LLC boosted its stake in shares of Zoetis by 1,387.5% during the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after buying an additional 222 shares during the last quarter. Finally, Central Valley Advisors LLC acquired a new stake in shares of Zoetis during the second quarter worth approximately $49,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 1.5 %

Zoetis stock opened at $176.82 on Friday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.09 and a current ratio of 3.69. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The company has a 50-day simple moving average of $188.15 and a 200-day simple moving average of $179.35. The firm has a market capitalization of $79.78 billion, a P/E ratio of 33.24, a P/E/G ratio of 2.61 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.36 EPS. As a group, equities analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio is currently 32.52%.

Analyst Ratings Changes

ZTS has been the topic of a number of research analyst reports. BTIG Research increased their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Piper Sandler boosted their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus upped their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, JPMorgan Chase & Co. upped their price target on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.